381 related articles for article (PubMed ID: 35494078)
1. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
[TBL] [Abstract][Full Text] [Related]
3. Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.
Maiorano BA; De Giorgi U; Ciardiello D; Schinzari G; Cisternino A; Tortora G; Maiello E
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203620
[TBL] [Abstract][Full Text] [Related]
4. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
5. Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Ciardiello D; Maglione A; Orditura M; Lorusso D; Maiello E
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497437
[TBL] [Abstract][Full Text] [Related]
6. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Maiorano BA; Maiorano MFP; Lorusso D; Maiello E
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503248
[TBL] [Abstract][Full Text] [Related]
7. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
9. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
10. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
Tinker AV; Dhani NC; Ghatage P; McLeod D; Samouëlian V; Welch SA; Altman AD
Ther Adv Med Oncol; 2023; 15():17588359231157633. PubMed ID: 36950270
[TBL] [Abstract][Full Text] [Related]
11. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Green AK; Feinberg J; Makker V
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Liu T; Jin B; Chen J; Wang H; Lin S; Dang J; Li G
Ther Adv Med Oncol; 2020; 12():1758835920940927. PubMed ID: 32774474
[TBL] [Abstract][Full Text] [Related]
14. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials.
Zhang F; Liu Z; Liang J; Zhang F; Wu K; Zhou C; Lu Y; Wang X
Clin Transl Oncol; 2020 Oct; 22(10):1750-1761. PubMed ID: 32086783
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study.
Ma S; Chen R; Duan L; Li C; Yang T; Wang J; Zhao D
J Gastrointest Oncol; 2023 Apr; 14(2):1052-1063. PubMed ID: 37201046
[TBL] [Abstract][Full Text] [Related]
19. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Cao R; Ma JT; Zhang SL; Sun L; Liu Y; Zhang XY; Jing W; Huang LT; Han CB
Cancer Med; 2019 Sep; 8(11):5033-5046. PubMed ID: 31297962
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
Expert Rev Anticancer Ther; 2024 Jun; ():1-13. PubMed ID: 38863432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
